Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Research and development costs | $ 87,000 | $ 110,000 | ||
Common Stock Options [Member] | ||||
Antidilutive securities excluded from computation of net loss per share, amount | 11,715,480 | 8,515,480 | ||
Common Stock Warrants [Member] | ||||
Antidilutive securities excluded from computation of net loss per share, amount | 1,153,845 | 5,337,345 | ||
Conversion of Debentures [Member] | ||||
Antidilutive securities excluded from computation of net loss per share, amount | 1,650,000 | 1,650,000 | ||
Conversion of shares | 52,180,859 | |||
Conversion price per share | $ 0.079 | $ 0.082 | $ 0.079 | $ 0.082 |
Conversion of Redeemable Convertible Preferred Stock [Member] | ||||
Antidilutive securities excluded from computation of net loss per share, amount | 7,569,210 | 41,984,478 | ||
Conversion of shares | 6,000,000 |
X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|